Skip to content
Triangle logo TriangleGet started
← Malignant Mesothelioma

NCT00770120 · STUDY IN CONTEXT

S0722: Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery

Draft scope assessment: narrower. Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.

Read the full study record and all posted results →

Linked outcomes

Measures are not ranked. Open each original source section for treatment groups, denominators, units and results.

primary · POSTED

Progression-Free Survival was defined as the duration from the date of registration until the date of disease progression per RECIST or death due to any cause. Patients known to be alive without evidence of disease progression were censored at the date of last contact. Disease progression was defined as a \>= 20% increase over nadir in the sum of longest diameters of target lesions, unequivocal progression of non-target lesions in the opinion of the treating investigator, appearance of new lesions, symptomatic deterioration, or death due to disease

Source null

→

secondary · POSTED

A response was defined as either a confirmed or unconfirmed complete or partial responses as defined by RECIST. A complete response (CR) was defined as the disappearance of all disease. A partial response (PR) was defined as a \>= 30% decrease in the sum of longest diameters of target lesions. A CR or PR was considered confirmed if two consecutive determinations were made at least 4 weeks apart.

Source null

→

secondary · POSTED

Overall survival was defined as the duration between the date of enrollment and the date of death due to any cause. Patients last known to be alive were censored at the date of last contact.

Source null

→

secondary · POSTED

Frequency and Severity of Toxicities

Number of Subjects With Greater Than Grade 2 Toxicity

→

Reported safety

Serious events are not the same as severe events. Compare the original safety groups and their at-risk populations.

Open the study safety table →

Quality of life and patient-reported measures

No linked quality-of-life measure is recorded for this setting and study.

Full draft applicability and source-link record
trial
release id
clinical-indications-draft-1
disease state id
ds-malignant-mesothelioma
nct id
NCT00770120
trial label
S0722: Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
applicability
narrower
applicability note
Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
provenance class
registry-condition-search
discovery note
Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
outcome Count
4
harms Count
1
qol Count
0
outcomes
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-malignant-mesothelioma
    nct id
    NCT00770120
    outcome key
    om-0000
    source section id
    NCT00770120-om-0000
    source outcome index
    0
    endpoint
    Progression-Free Survival
    endpoint definition
    Progression-Free Survival was defined as the duration from the date of registration until the date of disease progression per RECIST or death due to any cause. Patients known to be alive without evidence of disease progression were censored at the date of last contact. Disease progression was defined as a \>= 20% increase over nadir in the sum of longest diameters of target lesions, unequivocal progression of non-target lesions in the opinion of the treating investigator, appearance of new lesions, symptomatic deterioration, or death due to disease
    time origin
    Every 8 weeks until disease progression, up to 3 years.
    analysis role
    primary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  2. release id
    clinical-indications-draft-1
    disease state id
    ds-malignant-mesothelioma
    nct id
    NCT00770120
    outcome key
    om-0001
    source section id
    NCT00770120-om-0001
    source outcome index
    1
    endpoint
    Response
    endpoint definition
    A response was defined as either a confirmed or unconfirmed complete or partial responses as defined by RECIST. A complete response (CR) was defined as the disappearance of all disease. A partial response (PR) was defined as a \>= 30% decrease in the sum of longest diameters of target lesions. A CR or PR was considered confirmed if two consecutive determinations were made at least 4 weeks apart.
    time origin
    Every 8 weeks until disease progression, up to 3 years.
    analysis role
    secondary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  3. release id
    clinical-indications-draft-1
    disease state id
    ds-malignant-mesothelioma
    nct id
    NCT00770120
    outcome key
    om-0002
    source section id
    NCT00770120-om-0002
    source outcome index
    2
    endpoint
    Overall Survival
    endpoint definition
    Overall survival was defined as the duration between the date of enrollment and the date of death due to any cause. Patients last known to be alive were censored at the date of last contact.
    time origin
    Every 8 weeks until disease progression, up to 3 years.
    analysis role
    secondary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  4. release id
    clinical-indications-draft-1
    disease state id
    ds-malignant-mesothelioma
    nct id
    NCT00770120
    outcome key
    om-0003
    source section id
    NCT00770120-om-0003
    source outcome index
    3
    endpoint
    Frequency and Severity of Toxicities
    endpoint definition
    Frequency and Severity of Toxicities
    time origin
    Weekly during the first 8 weeks of treatment, then every 4 weeks while on treatment, then every 8 weeks until disease progression, then every 6 months thereafter.
    analysis role
    secondary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Number of Subjects With Greater Than Grade 2 Toxicity
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
arms
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-malignant-mesothelioma
    nct id
    NCT00770120
    outcome key
    om-0000
    arm key
    OG000
    arm label
    Everolimus
    regimen
    Daily oral Everolimus 10 mg/day everolimus
    analyzed count
    59
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00770120-om-0000#groups/OG000
  2. release id
    clinical-indications-draft-1
    disease state id
    ds-malignant-mesothelioma
    nct id
    NCT00770120
    outcome key
    om-0001
    arm key
    OG000
    arm label
    Everolimus
    regimen
    Daily oral Everolimus 10 mg/day everolimus
    analyzed count
    45
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00770120-om-0001#groups/OG000
  3. release id
    clinical-indications-draft-1
    disease state id
    ds-malignant-mesothelioma
    nct id
    NCT00770120
    outcome key
    om-0002
    arm key
    OG000
    arm label
    Everolimus
    regimen
    Daily oral Everolimus 10 mg/day everolimus
    analyzed count
    59
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00770120-om-0002#groups/OG000
  4. release id
    clinical-indications-draft-1
    disease state id
    ds-malignant-mesothelioma
    nct id
    NCT00770120
    outcome key
    om-0003
    arm key
    OG000
    arm label
    Everolimus
    regimen
    Daily oral Everolimus 10 mg/day
    analyzed count
    59
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00770120-om-0003#groups/OG000
harms
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-malignant-mesothelioma
    nct id
    NCT00770120
    harm key
    EG000
    source section id
    NCT00770120-ae
    event group key
    EG000
    event group label
    Everolimus
    serious affected
    25
    serious at risk
    59
    other affected
    58
    other at risk
    59
    frequency threshold
    5
    collection period
    From date of registration to 3 years post registration or death (whichever occurs first).
    event definition
    All SAEs and AEs.
    undenominated note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
quality of life
    setting source links

      Preserved source evidence · Not medical advice